Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protocol for AI-powered classification of IDH-mutant astrocytoma using GUIDE.

STAR protocols - 19 Jun 2026

Tang Jihong, Qiao Yimeng, Ruan Yuyan, Wang Jiguang

Abstract excerpt

Accurate identification of prognostic cancer subtypes remains challenging using routine diagnostics alone. Here, we present a protocol to obtain isocitrate dehydrogenase (IDH)-mutant astrocytoma subtype predictions using the generic utility for immune/mesenchymal-enriched (IME) diagnostic estimation (GUIDE). We describe steps for preparation of image and omics inputs, setup of the GUIDE Docker container,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Artificial Intelligence
Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 42060460
DOI: 10.1016/j.xpro.2026.104512
PMCID: PMC13136704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protocol for AI-powered classification of IDH-mutant astrocytoma using GUIDE.PMID 42060460Read ↗

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.Semantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.Semantic proximity Read ↗

Multi-omics integrative analysis of the glioma microenvironment reveals IDH-dependent cellular communication and prognostic signaturesSemantic proximity Read ↗

Immune landscape of isocitrate dehydrogenase stratified human gliomasSemantic proximity Read ↗

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seqSemantic proximity Read ↗

Updating TCGA glioma classification through integration of molecular profiling data following the 2016 and 2021 WHO guidelinesSemantic proximity Read ↗

Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.Semantic proximity Read ↗

Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.Semantic proximity Read ↗

Immune-Suppressed, Not Immune-Cold: HMOX1-CD14-Immunoproteasome Axis and Structure-Guided Combination Pharmacotherapies in Isocitrate Dehydrogenase-Mutant Glioblastoma.Semantic proximity Read ↗

Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.